Strive for excellence with an emphasis on fundamentals and innovations: interpretation of the WHO Global Tuberculosis Report 2022

doi:10.19982/j.issn.1000-6621.20230102

Abstract

Abstract:

Tuberculosis (TB) prevention and control work needs innovative research and development to accelerate the implementation of the World Health Organization (WHO) End TB Strategy. On 27th October 2022, WHO released the Global Tuberculosis Report 2022, updating the latest progress of global TB research and innovation. This paper reviews the key achievements in the areas of research and innovation for new diagnostics, drugs and regimens as well as vaccines introduced in the report, and discusses some of China’s indigenous progresses in related areas. This paper aims to make China’s TB professionals better informed about the latest research development in TB prevention and control around the globe, fostering indigenous TB innovation efforts with greater originality.

Key words: Tuberculosis, Research, Consensus development conference

CLC Number:

Shu Wei, Liu Yuhong. Strive for excellence with an emphasis on fundamentals and innovations: interpretation of the WHO Global Tuberculosis Report 2022[J]. Chinese Journal of Antituberculosis, 2023, 45(5): 454-457. doi: 10.19982/j.issn.1000-6621.20230102

References 8

[1]	World Health Organization.Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[2]	World Health Organization.The end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: World Health Organization, 2014.
[3]	Floyd K, Glaziou P, Houben RMGJ, et al. Global tuberculosis targets and milestones set for 2016—2035: definition and rationale. Int J Tuberc Lung Dis, 2018, 22(7): 723-730. doi:10.5588/ijtld.17.0835. doi: 10.5588/ijtld.17.0835 pmid: 29914597
[4]	Treatment Action Group, Stop TB Partnership. Tuberculosis research funding trends 2005—2020. New York: Treatment Action Group, 2021.
[5]	Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet, 2022, 400(10366): 1858-1868. doi:10.1016/S0140-6736(22)02078-5. doi: 10.1016/S0140-6736(22)02078-5 pmid: 36368336
[6]	Turkova A, Wills GH, Wobudeya E, et al. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. N Engl J Med, 2022, 386(10): 911-922. doi:10.1056/NEJMoa2104535. doi: 10.1056/NEJMoa2104535 URL
[7]	Gebreselassie N, Hutubessy R, Vekemans J, et al. The case for assessing the full value of new tuberculosis vaccines. Eur Respir J, 2020, 55(3): 1902414. doi:10.1183/13993003.02414-2019. doi: 10.1183/13993003.02414-2019 URL
[8]	World Health Organization. Evidence and research gaps identified during development of policy guidelines for tuberculosis. Geneva: World Health Organization, 2021.

[1]	Liao Yixuan, Fang Chuangsen, Li Yanming. Strengthening the capability of non-tuberculosis-designated medical institutions to improve the diagnosis of tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 437-441.
[2]	Wang Dakuan, Zhang Bin, Liu Zisen, Duan Weitao, Gao Lei. Exploration and prospect of the construction of primary tuberculosis preventive treatment clinic [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 442-445.
[3]	Li Shanshan, Wang Yufeng, Shu Wei, Pang Yu. Progress and reflections on development of laboratory diagnostic technology for tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 446-453.
[4]	Xia Hui, Zhao Yanlin. Interpretation of the World Health Organization’s Practical Manual on Tuberculosis Laboratory Strengthening (2022 Update) and consideration on strengthening tuberculosis laboratory network in China [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 458-463.
[5]	Shi Yuting, Dong Jing, Jia Hongyan, Zhu Chuanzhi, Yang Bin, Li Zihui, Sun Qi, Du Boping, Xing Aiying, Zhang Zongde, Pan Liping. The role of miR-99a-5p in the immune regulation of host macrophages infected by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 464-471.
[6]	Song Ruixue, Wei Rongrong, Dong Jing, Jia Hongyan, Du Boping, Sun Qi, Xing Aiying, Li Zihui, Zhu Chuanzhi, Zhang Zongde, Pan Liping. The performance of interferon gamma-induced protein 10 mRNA detection technology in auxiliary diagnosis of tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 471-476.
[7]	Li Hongna, Mao Xin, Xu Biyu, Wu Chenyang, Dong Liru, Song Xudong. Clinical value of common in situ pathological staining in diagnosis of pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 477-482.
[8]	Yan Xiaojing, Wang Qingfeng, Yang Yang, Chu Naihui, Nie Wenjuan. Diagnostic value of a nanopore sequencing assay of bronchoalveolar lavage fluid in smear-negative pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 487-492.
[9]	Zhang Xin, Liu Tao, Shi Zhiguo, Zhai Wenting, Chen Bin, Liu Wei. Effect of sugammadex on plasma concentration of rocuronium and muscle relaxation recovery in elderly patients with pulmonary tuberculosis after lobectomy [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 493-498.
[10]	Li Xiang, Qi Min, Jiang Jianjie, Wei Jialu, Fu Xuwen, Li Haiwen, Zhang Le. Analysis of risk factors for acute cerebral infarction combined with intracranial tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 499-506.
[11]	Meiheriban·Maimaiti , Mawlanjan·Emam , Lu Dongmei, Zheng Yanling, Zhang Xueliang, Peng Xiaowang. Study on the effect of daily average temperature on the incidence of tuberculosis in Shufu County at Xinjiang, based on a distributed lag nonlinear model [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 507-513.
[12]	Ren Feilin, Liu Xiaoqi, Jin Meihua, Sun Xiuxiu. Study on the predictive effect of seasonal auto regressive integrated moving average model on the incidence of pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 514-519.
[13]	Yang Jun, Deng Qiang, Peng Randong, Li Junjie, Wang Yurong, Yang Haiyun, Du Jianqiang. Establishment and research progress of rabbit model of spinal tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 520-525.
[14]	Zhao Aihua, Du Weixin, Wang Guozhi, Xu Miao. Discussion on the nomenclature of recombinant Mycobacterium tuberculosis allergen skin test [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 333-335.
[15]	Fu Liang, Ren Tantan, Zhang Peize, Lu Shuihua. Interpretation of WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 336-348.